136-150 of 937
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart MattersStaging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Heart MattersAnalyzing Outpatient Worsening Heart Failure in ATTR-CM
Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Heart MattersCurrent and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Ahmad Masri, MD, MS
Shared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
Heart MattersShared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
Ahmad Masri, MD, MS
The Far-Reaching Impacts of Psoriasis: Understanding and Mitigating Risks
DermConsultThe Far-Reaching Impacts of Psoriasis: Understanding and Mitigating Risks
Jenny Murase, MD
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Parul Rai
- advertisement
Partnering for Better Hypertension Outcomes: How AMA and Azara Support Providers
Perspectives with the AMAPartnering for Better Hypertension Outcomes: How AMA and Azara Support Providers
Charles Turck, PharmD, BCPS, BCCCP
Jeff Brandes
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
On the Frontlines of COPDECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Raymond Wade, MD
Scaling Success: Hypertension Control at MPCA with the AMA MAP™ Program
Perspectives with the AMAScaling Success: Hypertension Control at MPCA with the AMA MAP™ Program
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Faiyaz Syed MD, MPH
Skin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection
On the Frontlines of PsoriasisSkin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Joel M. Gelfand, MD, MSCE, FAAD
Michael S. Garshick, MD
Topline Results of the CONFIDENCE Trial
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Topline Results of the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
The CONFIDENCE Trial: Data Insights
DataPulse: Key Clinical Trial Insights on Nonsteroidal MRAs in CKM Syndrome ManagementThe CONFIDENCE Trial: Data Insights
prof. Hiddo Heerspink
- advertisement
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Finnian R. McCausland, MD
Albuminuria Change and Finerenone's Effect on CV Outcomes
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Albuminuria Change and Finerenone's Effect on CV Outcomes
Finnian R. McCausland, MD
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Heart MattersImproving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
